Opioid Long-Term Effectiveness: FDA Postmarket Trial Design Offers ‘Best Compromise’

FDA advisory committee to consider proposed protocol to meet postmaketing requirement set a decade ago to determine risk of hyperalgesia following long-term use of ER/LA opioid analgesics. Initial trial was terminated in 2018 due to inability to recruit enough patients.

Opioid prescription
FDA panel to discuss postmarket clincial trial on long-term effectiveness of opioid analgesics • Source: Shutterstock

A decade after the US Food and Drug Administration required makers of extended-release and long-acting opioid analgesics to conduct a post-marketing study on the risk of opioid-induced hyperalgesia, manufacturers and the agency have a proposed protocol for review by its outside experts.

The agency’s Anesthetic and Analgesic Drug Products Advisory Committee will discuss the protocol at its 19 April meeting. In its...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

Ocaliva Confirmatory Trial Failed To Verify Benefit In Primary Biliary Cholangitis, US FDA Says

 
• By 

A real-world evidence study also does not meet the regulatory standard for an adequate and well-controlled clinical investigation, the agency said. The FDA should allow the accelerated approval drug to remain available like other treatments that failed their confirmatory trials, Intercept said.  

Recent And Upcoming FDA Advisory Committee Meetings

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered. 

EU Filings Tracker TEST

New marketing authorization applications filed with the European Medicines Agency's human medicines committee (the CHMP) for review under the EU's centralized procedure. Updated monthly.

US FDA Adcomm Reform Ideas: Neutral Facilitator As Chair, Public Hearing Lottery Process Tweaks

 
• By 

Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.

More from Regulatory Trackers

Ocaliva Confirmatory Trial Failed To Verify Benefit In Primary Biliary Cholangitis, US FDA Says

 
• By 

A real-world evidence study also does not meet the regulatory standard for an adequate and well-controlled clinical investigation, the agency said. The FDA should allow the accelerated approval drug to remain available like other treatments that failed their confirmatory trials, Intercept said.  

Global Pharma Guidance Tracker – August 2024

 
• By 

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Recent And Upcoming FDA Advisory Committee Meetings

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.